Trevena, Inc. (TRVN)

USD 1.28

(1.59%)

Market Cap (In USD)

1.1 Million

Revenue (In USD)

3.12 Million

Net Income (In USD)

-40.28 Million

Avg. Volume

2376.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.13-19.225
PE
-0.03
EPS
-48.89
Beta Value
1.016
ISIN
US89532E2081
CUSIP
89532E109
CIK
1429560
Shares
863788.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Carrie L. Bourdow
Employee Count
-
Website
https://www.trevena.com
Ipo Date
2014-01-31
Details
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.